United Imaging Receives Contract from Vizient for its X-ray and Magnetic Resonance Imaging Systems

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has received a contract from Vizient, Inc., for its entire portfolio of DR (X-Ray) and MR (magnetic resonance) systems.

United Imaging notes the contract expands the number of modalities offered through Vizient by United Imaging, which last year also received a contract for its suite of cutting-edge CT (computed tomography) equipment.

Vizient is the largest member-driven health care performance improvement company in the country with a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents more than $110 billion in annual purchasing volume.

United Imaging takes a highly vertically integrated approach to innovation to help manage both quality and costs and enable the most cutting-edge technology across all its modalities. In addition, the company’s bold approach to the U.S. market includes several unique aspects.

All-in ConfigurationsTM means that its systems are sold fully loaded with all available features included from the outset, giving customers the flexibility to immediately or in the future provide advanced offerings to patients without additional upgrade costs. Software Upgrades for Life TM refers to the company’s groundbreaking commitment to provide the latest software upgrades throughout the product lifecycle across its entire installed base at no additional cost to the healthcare provider, helping them provide the highest standards of care.

United Imaging also offers a United Performance Guarantee on all full-service agreements, flexible coverage options for in-house biomedical engineer organizations, and customized financing solutions to streamline buying and owning medical equipment.

“We are excited to receive another contract with Vizient,” said Jeffrey M. Bundy, Ph.D, CEO of United Imaging Healthcare Solutions. “Through this contract, we hope to help more healthcare organizations improve the quality of their patient care.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”